Back to funds
View filing
DAFNA Capital Management LLC
hedge fundUpdated 27 days agoManaged by Dafna Capital Management Llc • Latest filing Q2 2026
Portfolio value
$524.4M
Q2 2026
Filings
14
Quarterly 13F history
Top-10 concentration
100.0%
Weight of largest holdings
Annualized return
9.6%
Implied from 13F holdings
Portfolio value history
13F-disclosed portfolio value over 14 quarters
Show data table
| Period | Portfolio value |
|---|---|
| Q1 2023 | $333.5M |
| Q2 2023 | $365.7M |
| Q3 2023 | $321.5M |
| Q4 2023 | $417.3M |
| Q1 2024 | $439.3M |
| Q2 2024 | $418.6M |
| Q3 2024 | $423.3M |
| Q4 2024 | $393.4M |
| Q1 2025 | $352.7M |
| Q2 2025 | $362.3M |
| Q3 2025 | $404.8M |
| Q4 2025 | $430.5M |
| Q1 2026 | $439.6M |
| Q2 2026 | $524.4M |
Top holdings
88 positions as of Q2 2026
| # | Stock | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|---|
| 1 | R RVMDW REVOLUTION MEDICINES INC | $105.4M | 562.6K | 20.09% | — |
| 2 | S STT-PG SPDR S&P BIOTECH ETF | $31.1M | 196.5K | 5.93% | — |
| 3 | C CMPS COMPASS PATHWAYS PLC | $28.5M | 2.01M | 5.43% | — |
| 4 | S STXS STEREOTAXIS INC | $23.5M | 13.68M | 4.49% | — |
| 5 | N NKTR NEKTAR THERAPEUTICS | $22.2M | 318.4K | 4.24% | — |
| 6 | D DNLI DENALI THERAPEUTICS INC | $19M | 739.0K | 3.62% | — |
| 7 | I IDYA IDEAYA BIOSCIENCES INC | $18.5M | 497.2K | 3.53% | — |
| 8 | A ATRC ATRICURE INC | $16.7M | 597.4K | 3.19% | — |
| 9 | X XENE XENON PHARMACEUTICALS INC | $15.1M | 250.8K | 2.89% | — |
| 10 | C CYTK CYTOKINETICS INC | $14.7M | 172.0K | 2.79% | — |
| 11 | R RCUS ARCUS BIOSCIENCES INC | $13.6M | 441.8K | 2.60% | — |
| 12 | A ASND ASCENDIS PHARMA A/S | $12.9M | 48.5K | 2.47% | — |
| 13 | N NBIX NEUROCRINE BIOSCIENCES INC | $9.7M | 57.8K | 1.86% | — |
| 14 | A AXGN AXOGEN INC | $9.7M | 209.0K | 1.84% | — |
| 15 | P PODD INSULET CORP | $9.4M | 61.9K | 1.80% | — |
| 16 | E EWTX EDGEWISE THERAPEUTICS INC | $9.2M | 226.8K | 1.76% | — |
| 17 | B BCAX BICARA THERAPEUTICS INC | $8.5M | 285.0K | 1.61% | — |
| 18 | E ETHA ISHARES NASDAQ BIOTECH INDX | $8.1M | 42.6K | 1.54% | — |
| 19 | S SNDX SYNDAX PHARMACEUTICALS INC | $7.3M | 335.3K | 1.40% | — |
| 20 | M MPLT MAPLIGHT THERAPEUTICS INC | $6.1M | 171.0K | 1.17% | — |